Stat3 Activation as a Potential Prognostic Marker and Therapeutic Target in Pediatric AML-II
N/A
30 Years
Both
Leukemia
Trial Information
Stat3 Activation as a Potential Prognostic Marker and Therapeutic Target in Pediatric AML-II
OBJECTIVES:
Primary
- To determine the percentage of primary acute myeloid leukemia (AML) samples with
increased Stat3 signaling pathway activity.
- To evaluate the presence of constitutive Stat3 activation and the sensitivity of Stat3
activation to low- and high-doses of cytokines.
- To evaluate the expression levels of Stat3 protein and the upstream and downstream
regulators of Stat3 activation.
Secondary
- To classify samples according to a Stat3 activation pattern and correlate this result
with event-free survival (EFS) and overall survival (OS).
OUTLINE: Cryopreserved AML specimens are analyzed for pStat3 and pStat5 levels, response to
cytokine levels, and expression level of proteins known to influence stat activity by flow
cytometry and western blot assays. Results are also compared with prognostic variables
determined in CCG-291 study, including age, race, WBC, and cytogenetic risks.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of acute myeloid leukemia (AML)
- Cryopreserved AML specimens
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Correlation of constitutive pStat3 with inducible pStat3
Safety Issue:
No
Principal Investigator
Michele S. Redell, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Texas Children's Cancer Center
Authority:
United States: Federal Government
Study ID:
CDR0000689410
NCT ID:
NCT01245231
Start Date:
November 2010
Completion Date:
Related Keywords:
- Leukemia
- childhood acute myeloid leukemia/other myeloid malignancies
- Leukemia
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid
Name | Location |
|---|
